Skip to main content Back to Top
Advertisement

11/16/2021

Doxycycline Oral Suspension

Products Affected - Description

    • Vibramycin Monohydrate oral powder for suspension, Pfizer, 25 mg/5 mL, 60 mL bottle, NDC 00069-0970-65 - discontinued
    • Vibramycin calcium oral suspension, Pfizer, 50 mg/5 mL, 473 mL bottle, NDC 00069-0971-95
    • Doxycycline monohydrate oral powder for suspension, Cipla USA, 25 mg/5 mL, 60 mL bottle, NDC 69097-0228-43 - discontinued

Reason for the Shortage

    • Cipla discontinued doxycycline monohydrate powder for oral suspension in 2021.
    • Pfizer has Vibramycin Calcium oral suspension on shortage due to manufacturing delay.
    • Pfizer discontinued Vibramycin Monohydrate powder for oral suspension in November 2021.
    • Lupin has doxycycline monohydrate powder for oral suspension available.

Available Products

    • Doxycycline monohydrate oral powder for suspension, Lupin, 25 mg/5 mL, 60 mL bottle, NDC 68180-0657-01

Estimated Resupply Dates

    • Pfizer has Vibramycin calcium oral suspension 50 mg/5 mL in 473 mL bottles on back order and the company cannot estimate a release date.

Updated

Created November 16, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.